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MaBACKGROUND The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recom-
mend primary prevention with statins for individuals with $7.5% 10-year risk for atherosclerotic cardiovascular disease
(ASCVD). Everyone living long enough will become eligible for risk-based statin therapy due to age alone.
OBJECTIVES This study sought to personalize ACC/AHA risk-based statin eligibility using noninvasive assessment of
subclinical atherosclerosis.
METHODS In 5,805 BioImage participants without known ASCVD at baseline, those with $7.5% 10-year ASCVD risk
were down-classiﬁed from statin eligible to ineligible if imaging revealed no coronary artery calcium (CAC) or carotid
plaque burden (cPB). Intermediate-risk individuals were up-classiﬁed from optional to clear statin eligibility if CAC
was $100 (or equivalent cPB).
RESULTS At a median follow-up of 2.7 years, 91 patients had coronary heart disease and 138 had experienced a cardio-
vascular disease event. Mean age of the participants was 69 years, and 86% qualiﬁed for ACC/AHA risk-based statin therapy,
with high sensitivity (96%) but low speciﬁcity (15%). CAC or cPB scores of 0 were common (32% and 23%, respectively) and
were associatedwith low event rates.With CAC-guided reclassiﬁcation, speciﬁcity for coronary heart disease events improved
22% (p < 0.0001) without any signiﬁcant loss in sensitivity, yielding a binary net reclassiﬁcation index (NRI) of 0.20
(p< 0.0001). With cPB-guided reclassiﬁcation, speciﬁcity improved 16% (p< 0.0001) with a minor loss in sensitivity (7%),
yielding an NRI of 0.09 (p ¼ 0.001). For cardiovascular disease events, the NRI was 0.14 (CAC-guided) and 0.06
(cPB-guided). The positive NRIs were driven primarily by down-classifying the large subpopulation with CAC¼ 0 or cPB¼ 0.
CONCLUSIONS Withholding statins in individuals without CAC or carotid plaque could spare a signiﬁcant proportion
of elderly people from taking a pill that would beneﬁt only a few. This individualized disease-guided approach is
simple and easy to implement in routine clinical practice. (J Am Coll Cardiol 2016;68:881–91) © 2016 by the American
College of Cardiology Foundation. Published by Elsevier. This is an open access article under the CC BY license
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ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College of
Cardiology
AHA = American Heart
Association
ASCVD = atherosclerotic
cardiovascular disease
CAC = coronary artery calcium
CHD = coronary heart disease
cPB = carotid plaque burden
CVD = cardiovascular disease
MI = myocardial infarction
PCE = Pooled Cohort Equations
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882I n 2013, the American College of Cardiol-ogy (ACC) and the American Heart Asso-ciation (AHA) released new guidelines
on risk assessment (1) and cholesterol treat-
ment (2). For use in primary prevention of
atherosclerotic cardiovascular disease
(ASCVD), a new risk model on the basis of
the Pooled Cohort Equations (PCE) was intro-
duced (1), together with an online ASCVD risk
calculator (3). The indication for statin ther-
apy in individuals without ASCVD or diabetes
was expanded by lowering the threshold for
treatment to $7.5% 10-year ASCVD risk esti-
mated by the PCE-based risk calculator (Class
I recommendation) (2). That threshold toinitiate statin therapy was supported by risk-beneﬁt
and cost-effectiveness analyses (1,2,4).SEE PAGE 892With the growing elderly population, the dominant
effect of age on eligibility for statin therapymight need
reconsideration (5–7). All healthy people with optimal
cardiovascular risk factors will automatically, due to
age-related risk alone, pass the 7.5% 10-year ASCVD
risk threshold and qualify for ACC/AHA-recommended
statin therapy between age 63 and 71 years (depending
on sex and ethnicity). This universal eligibility for
statin therapy with aging will inevitably lead to over-
treatment of many older individuals who do not have
the disease (atherosclerosis) that the treatment is
intended to prevent or stabilize. Another related
concern: PCEs tend to overestimate 10-year ASCVD
risk in contemporary lower-risk populations, which
also may lead to overtreatment (2,8–10).
The purpose of the present study was to evaluate a
more personalized approach to primary prevention
with statins by adding a simple disease-guided
reclassiﬁcation step after formal ACC/AHA-
recommended risk assessment. Thus, the decision to
treat with statins is simply guided by the absence (do
not treat) or presence (treat) of subclinical athero-
sclerosis detected by noninvasive imaging of the cor-
onary and carotid arteries (Central Illustration). We
tested this practical, disease-guided reclassiﬁcation
approach to statin allocation for primary prevention of
ASCVD in the contemporary, multiethnic BioImage
cohort.
METHODS
The design and objectives of the BioImage Study
(NCT00738725) have been published previously (11).
BioImage was a prospective observational cohort of
men 55 to 80 years of age and women 60 to 80 yearsof age without known ASCVD at baseline examination
between January 2008 and June 2009. The BioImage
cohort is sex-balanced and included racial/ethnic
minorities corresponding to the overall U.S. popula-
tion. The primary objective was to identify predictive
biomarkers for near-term ASCVD events in the
noninvasive imaging group (n ¼ 6,102) (12). The study
was approved by the Western Institutional Review
Board, Olympia, Washington. Informed consent and
Health Insurance Portability and Accountability
Act authorization were obtained from all study
participants.
Baseline examination included assessment of car-
diovascular risk factors and screening for subclinical
(asymptomatic) atherosclerosis as previously
described (12) and speciﬁed in the Online Appendix.
All study participants underwent noncontrast
computed tomography scanning to determine the
Agatston coronary artery calcium (CAC) score and
carotid ultrasound imaging to detect and quantify
carotid plaque. By using a novel sweep method,
described previously (13) and in the Online Appendix,
all cross-sectional plaque areas were summed as ca-
rotid plaque burden (cPB).
DISEASE-GUIDED RECLASSIFICATION. The PCEs are
applicable to ASCVD-free individuals 40 to 79 years of
age (1). The ACC/AHA guidelines (2) deﬁne 4 statin-
beneﬁt groups; the following 3 are relevant for pri-
mary prevention of ASCVD (Class 1 recommendation):
1. Individuals without ASCVD or diabetes, 40 to 75
years of age, with a low-density lipoprotein
cholesterol (LDL-C) of 70 to 189 mg/dl, and with an
estimated 10-year ASCVD risk of $7.5%.
2. Individuals with diabetes, 40 to 75 years of age,
and LDL-C 70 to 189 mg/dl.
3. Individuals with primary elevations of LDL-C
$190 mg/dl
Additionally, statin therapy is reasonable when the
10-year ASCVD risk is 5% to <7.5% (Class IIa recom-
mendation) and might be considered at even lower
risk and beyond the age range of 40 to 75 years (Class
IIb recommendation) (2).
Accepting these recommended cut-points for pri-
mary prevention with statins as a useful starting
point, we tested the following disease-guided
reclassiﬁcation approach:
 To improve speciﬁcity (less overtreatment), in-
dividuals with $7.5% 10-year ASCVD risk estimated
by PCE are down-classiﬁed from statin eligible to
ineligible if CAC or cPB is absent.
 To improve sensitivity (less undertreatment), in-
dividuals with “intermediate” ASCVD risk (5%
CENTRAL ILLUSTRATION Disease-Guided Primary Prevention With Statins
Mortensen, M.B. et al. J Am Coll Cardiol. 2016;68(9):881–91.
(A) Following guideline-recommended formal risk assessment and atherosclerosis imaging, statin-eligible individuals are down-classiﬁed to ineligible in the absence of
atherosclerosis, and statin-ineligible individuals are up-classiﬁed to eligible if signiﬁcant atherosclerosis is present. This principle facilitates an informed clinician-patient
discussion, leading to an individualized treatment decision. (B) In the BioImage cohort, beneﬁcial reclassiﬁcation was achieved using coronary artery calcium (CAC) and
carotid plaque burden (cPB). ACC/AHA ¼ American College of Cardiology/American Heart Association; ASCVD ¼ atherosclerotic cardiovascular disease; CHD ¼ coronary
heart disease; CVD ¼ cardiovascular disease; NRI ¼ net reclassiﬁcation index.
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883to <7.5% estimated by PCE) are up-classiﬁed from
optional to statin eligible if the CAC is $100 or cPB
is $300 mm2 (equivalent to CAC $100).
CLINICAL OUTCOMES. The 2013 ACC/AHA guidelines
changed the predicted outcome from coronary heartdisease (CHD) to ASCVD (CHD þ stroke) using the
PCE-based risk calculator, and the threshold for statin
therapy was lowered (2). Consequently, the evidence
base for the clinical utility of atherosclerosis imaging
in risk assessment under the previous ACC/AHA
guidelines (14) was no longer applicable and needed
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884to be updated (1,2). To inform this revision, we pre-
sent results separately for the following outcomes:
1) CHD (spontaneous myocardial infarction [MI], un-
stable angina [UA], and coronary revascularization);
and 2) cardiovascular disease (CVD) (CHD þ ischemic
stroke, and cardiovascular death). An independent
clinical events committee used source medical re-
cords to adjudicate CHD and CVD events as described
in the Online Appendix.
STATISTICAL APPROACH. Baseline characteristics of
BioImage participants were analyzed according to 10-
year ASCVD risk estimated using the PCEs underlying
the ACC/AHA online risk calculator (1–3). To compare
the clinical performance of CAC and cPB, we created 3
comparable groups (zero, middle, and top) for each
modality, with a similar proportion of BioImage par-
ticipants in the 2 top groups. The top CAC group
comprised those with CAC $100, and the top cPB
group comprised those with cPB $300 mm2 (chosen
to match the percentile for CAC ¼ 100, giving 2 top
groups of similar size but selected differently). The
zero groups were absence of CAC (CAC ¼ 0) and cPB
(cPB ¼ 0), respectively. We then calculated the
number needed to screen (NNS) to identify 1 person
belonging to the zero or top group of subclinical
atherosclerosis by dividing 100 by the percentage of
people with the given amount of disease.
The association (hazard ratio [HR]) of CAC and cPB
groups with development of CHD and CVD was
assessed using Cox regression models analyzing time
to event. Analyses were multivariable and adjusted
for baseline characteristics. We used Kaplan-Meier
estimates of cumulative incidence to compare (log-
rank test) the occurrence of CHD and CVD events overTABLE 1 Baseline Characteristics
All
(N ¼ 5,805)
<5%
(n ¼ 318)
Age, yrs 68.9  6.0 61.8  2.8
Male 44 10
Diabetes 15 0
Current smokers 9 1
Hypertension 62 16
Systolic BP, mm Hg 139.5  18.5 120.9  12.6
Diastolic BP, mm Hg 78.2  9.1 74.0  8.2
Total cholesterol, mg/dl 202.5  38.6 204.6  36.0
HDL cholesterol, mg/dl 55.7  15.3 65.0  15.4
LDL cholesterol, mg/dl 114.2  33.2 112.5  30.2
Lipid-lowering medication 34 28
10-year ASCVD risk, % 19.3  12.3 3.8  0.8
Values are mean  SD or %. *Calculated by Pooled Cohort Equations.
ASCVD ¼ atherosclerotic cardiovascular disease; BP ¼ blood pressure; HDL ¼ high-detime according to zero, middle, and top groups of CAC
and cPB.
The clinical usefulness of assessing subclinical
atherosclerosis in addition to the ACC/AHA guidelines
depends on the ability to correctly reclassify in-
dividuals across decision thresholds. We therefore
calculated the sensitivity, speciﬁcity, and binary net
reclassiﬁcation index (NRI) after applying the
disease-guided reclassiﬁcation described in the pre-
vious text. In the ﬁrst analysis, only participants with
a 10-year ASCVD risk of $7.5% to 15% could be down-
classiﬁed from statin eligible to ineligible by absence
of CAC or cPB. In the second analysis, all participants
with a 10-year ASCVD risk of $7.5% could be down-
classiﬁed to statin ineligible. The binary NRI (to
treat or not to treat) is the sum of Dsensitivity and
Dspeciﬁcity and can be in the range of 2 to 2.
RESULTS
In the BioImage study, 6,102 participants underwent
noninvasive imaging to assess subclinical athero-
sclerosis. Due to missing data, 297 participants were
excluded, yielding a ﬁnal study population of 5,805
adults.
Per baseline characteristics (Table 1), the study
population’s mean age was 69 years, and 56% of
participants were women. The great majority (86%) of
the BioImage cohort was statin eligible because of an
estimated 10-year ASCVD risk $7.5%; risk was $15%
in 55% of participants (Central Illustration).
According to the relationship between cardiovas-
cular risk factors and subclinical atherosclerosis at
baseline (Table 2), 10-year ASCVD risk correlated10-Year ASCVD Risk*
5% to <7.5%
(n ¼ 521)
7.5% to <15%
(n ¼ 1,769)
$15%
(n ¼ 3,197)
63.6  4.0 66.2  4.7 71.9  5.1
23 36 54
2 6 23
17 7 11
30 52 78
127.4  13.5 134.7  16.0 145.9  18.1
75.8  7.9 78.1  8.9 79.1  9.2
205.6  35.7 206.8  37.3 199.4  39.7
60.7  15.4 57.2  14.8 53.1  14.9
114.6  31.1 117.7  32.7 112.3  34.0
29 30 38
6.3  5.0 11.1  2.2 27.4  10.8
nsity lipoprotein; LDL ¼ low-density lipoprotein.
TABLE 2 Baseline Cardiovascular Risk Factors and Subclinical Atherosclerosis
CAC cPB
0 (n = 1,852) 1–99 (n = 1,675) $100 (n = 2,278) 0 (n = 1,315) 1–299 (n = 2,212) $300 (n = 2,278)
Age, yrs 67.2  5.6 68.7  5.9 70.4  5.8 67.4  5.7 68.6  5.9 70.0  5.9
Male 29 41 58 34 48 55
Diabetes 11 14 18 13 13 17
Current smoker 6 8 10 4 7 12
Hypertension 55 60 69 56 58 69
Systolic BP, mm Hg 137.3  18.5 138.9  18.3 141.6  18.5 136.7  18.2 138.4  18.1 142.1  18.8
Diastolic BP, mm Hg 78.3  8.9 78.3  9.2 78.0  9.1 79.3  9.3 78.0  8.8 77.8  9.1
Total cholesterol, mg/dl 207.3  38.3 203.8  38.7 197.7  38.1 202.9  38.1 203.8  39.0 201  38.4
LDL cholesterol, mg/dl 117.6  32.5 114.7  33.5 110.9  33.3 114.1  32.5 114  33.2 114.0  33.6
HDL cholesterol, mg/dl 58.3  15.2 55.7  15.3 53.6  15.0 57.8  15.3 56.5  15.2 53.7  15.1
Lipid-lowering medication 27 35 40 45 34 38
Values are mean  SD or %, unless otherwise indicated.
CAC ¼ coronary artery calcium; cPB ¼ carotid plaque burden; other abbreviations as in Table 1.
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885directly with the amount of subclinical atheroscle-
rosis (Spearman correlation coefﬁcient: 0.36 for CAC
and 0.31 for cPB; p < 0.0001 for both). Absence of
atherosclerosis was most common in lower-risk per-
sons, whereas the opposite was true for the presence
of severe atherosclerosis (Figure 1). Furthermore, with
the methods used to assess subclinical disease in this
study, absence of atherosclerosis was more common
in the coronary arteries (32%) than in the carotid ar-
teries (23%). Among individuals with $7.5% 10-year
ASCVD risk, 28% had no CAC and 20% had no ca-
rotid plaque. The prevalence of signiﬁcantFIGURE 1 Severity of Subclinical Atherosclerosis Stratiﬁed by 10-Ye
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The prevalence of coronary artery calcium (CAC) ¼ 0 declined with incr
CAC $100. A similar pattern was seen for carotid plaque burden (cPB).atherosclerosis, deﬁned as CAC $100 or cPB $300,
was similar in the coronary and carotid arteries (39%).
The risk-dependent NNS to identify 1 person
with absence or signiﬁcant atherosclerosis is shown
in Table 3. Regarding the potential for down-
classiﬁcation, the NNS to ﬁnd 1 person with CAC ¼ 0
was 2.6 and 4.5 among people with 10-year ASCVD
risk of 7.5% to 15% and $15%, respectively. As for the
potential for up-classiﬁcation, the NNS to ﬁnd 1 per-
son with CAC $100 among people with 10-year
ASCVD risk of <5% and 5% to 7.5% was 10 and 5.3,
respectively. The same pattern was seen usingar ASCVD Risk
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easing risk calculated by the pooled cohort equations; the opposite happened for
ASCVD ¼ atherosclerotic cardiovascular disease.
TABLE 3 Risk-Dependent NNS for Subclinical Atherosclerosis
All
(N ¼ 5,805)
10-Year ASCVD Risk*
<5%
(n ¼ 318)
5% to <7.5%
(n ¼ 521)
7.5% to <15%
(n ¼ 1,769)
$15%
(n ¼ 3,197)
CAC ¼ 0 32 64 53 39 22
NNS 3.1 1.6 1.9 2.6 4.5
CAC $100 39 10 19 30 50
NNS 2.6 10 5.3 3.3 2.0
cPB ¼ 0 23 44 32 26 17
NNS 4.3 2.3 3.1 3.8 5.9
cPB $300 39 14 20 32 49
NNS 2.6 7.1 5.0 3.1 2.0
Values are % or NNS. *Calculated by Pooled Cohort Equations.
NNS ¼ number needed to screen to identify 1 individual with the value(s) in question; other abbreviations as in
Tables 1 and 2.
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up-classiﬁcation, respectively (Table 3).
CLINICAL EVENTS. Over a median follow-up of 2.7
years, 91 patients had a ﬁrst CHD event (MI, n ¼ 34;
UA, n ¼ 18; coronary revascularization without MI or
UA, n ¼ 39) and 138 patients had a ﬁrst CVD event
(in total: MI, n ¼ 34; UA, n ¼ 18; coronary revascu-
larization, n ¼ 39; ischemic stroke, n ¼ 30; cardio-
vascular death, n ¼ 27).
There was a strong relationship between subclini-
cal atherosclerosis and clinical events (Table 4). Event
rates were low in participants without subclinical
atherosclerosis, even those with diabetes. Only 1 and
2 clinical events were seen among patients with dia-
betes with CAC ¼ 0 and cPB ¼ 0, respectively. Kaplan-
Meier cumulative-event curves for CHD and CVD are
shown in Figure 2.
DISEASE-GUIDED RECLASSIFICATION. The ACC/AHA
risk-based approach to statin allocation had high
sensitivity (96%) but low speciﬁcity (15%) (Table 5).TABLE 4 Relationship Between Subclinical Atherosclerosis and Clinic
Subclinical
Atherosclerosis
Total
N (%)
CHD Events
n (%)
Event Rate per 1,000
Person-Years (95% CI)
CAC
0 1,852 (32.0) 4 (0.2) 0.85 (0.32–2.26)
1–99 1,675 (29.0) 18 (1.1) 4.11 (2.59–6.52) 4.7
$100 2,278 (39.0) 69 (3.0) 11.73 (9.26–14.85) 13.7
cPB
0 1,315 (23.0) 6 (0.5) 1.74 (0.78–3.88)
1–299 2,212 (38.0) 27 (1.2) 4.63 (3.16–6.81) 2.1
$300† 2,278 (39.0) 59 (2.6) 9.94 (7.71–12.84) 3.6
*Adjusted for age, sex, total cholesterol, LDL cholesterol, HDL cholesterol, systolic BP, sm
the percentile of CAC ¼ 100.
CHD ¼ coronary heart disease; CI ¼ conﬁdence interval; CVD ¼ cardiovascular diseaseFirst, we assessed the consequences of down-
classifying those with a 10-year ASCVD risk of 7.5%
to <15% from statin eligible to ineligible if CAC was 0,
and up-classifying those with an “intermediate”
ASCVD risk of 5% to <7.5% if CAC was $100 from
optional to clear statin eligible (Table 5, Online
Tables 1 and 2). The speciﬁcity increased substan-
tially from 15% to 25% for both CHD and CVD without
any signiﬁcant loss in sensitivity, leading to a binary
NRI of 0.11 for CHD and 0.08 for CVD. Then we
expanded the candidate population for down-
classiﬁcation to all with a 10-year ASCVD risk $7.5%
(not capped at 15%) and CAC ¼ 0. The gain in speci-
ﬁcity doubled, resulting in a binary NRI of 0.20 for
CHD and 0.14 for CVD (Table 5, Central Illustration).
These changes were driven mainly by down-
classifying the subpopulation with CAC ¼ 0 (Online
Tables 1 to 4).
Assessment of the binary disease-guided reclassi-
ﬁcation approach using cPB cut-points of 0 and 300
(equivalent to CAC ¼ 100) is shown in Table 5 and
Online Tables 5 to 8. Limiting down-classiﬁcation
(withholding statins) to those with 7.5% to <15% 10-
year ASCVD risk decreased sensitivity to nearly the
same extent as speciﬁcity increased, giving rise to no
net effect on NRI. However, if everyone with a 10-
year ASCVD risk $7.5% was down-classiﬁed to statin
ineligible if cPB was 0, the speciﬁcity increased more
than the sensitivity decreased (NRI ¼ 0.09 for CHD
and 0.06 for CVD) (Table 5, Central Illustration).
Excluding coronary revascularization from the
endpoints did not change the results. The HR for
CAC $100 and CHD events tended to be slightly lower
(Online Table 9), but CAC- and cPB-guided NRIs
remained similar for both CHD and CVD events,
driven by a substantial increase in speciﬁcity with no
or minimal loss in sensitivity (Online Table 10).al Events
CVD Events
HR*
(95% CI) n (%)
Event Rate per 1,000
Person-Years (95% CI)
HR*
(95% CI)
1 (reference) 15 (0.8) 3.19 (1.92–5.29) 1 (reference)
7 (1.37–15.55) 25 (1.5) 5.71 (3.86–8.45) 1.48 (0.75–2.92)
3 (4.23–44.59) 98 (4.3) 16.70 (13.70–20.36) 3.98 (2.20–7.18)
1 (reference) 15 (1.1) 4.37 (2.63–7.25) 1 (reference)
9 (0.89–5.39) 36 (1.6) 6.43 (4.63–8.91) 1.23 (0.67–2.26)
9 (1.55–8.75) 87 (3.8) 14.71 (11.92–18.15) 2.14 (1.20–3.78)
oking, lipid-lowering medication, race, and diabetes. †cPB ¼ 300 mm2 corresponds to
; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
FIGURE 2 Cumulative Incidence of Clinical Events
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Cumulative CHD by Coronary Artery Calcium (CAC)
p-value <0.0001 Cumulative CVD by Coronary Artery Calcium (CAC)p-value <0.0001
Cumulative CHD by Carotid Plaque Burden (cPB)
p-value <0.0001
Cumulative CVD by Carotid Plaque Burden (cPB)
p-value <0.0001
CAC ≥ 100
CAC 1-99
CAC = 0
CAC ≥ 100
CAC 1-99
CAC = 0
cPB ≥ 300
cPB 1-299
cPB = 0
cPB ≥ 300
cPB 1-299
cPB = 0
In the Kaplan-Meier cumulative-event curves for coronary heart disease (CHD) and cardiovascular disease (CVD) events, CAC ¼ 0 and cPB ¼ 0 were
associated with low event rates. Abbreviations as in Figure 1.
TABLE 5 Binary Disease-Guided Reclassiﬁcation Approaches* to Statin Allocation
Predicted Outcome
and Risk Model
Sensitivity Speciﬁcity DSensitivity DSpeciﬁcity Reclassiﬁcation
% % % p Value % p Value NRI p Value
CHD (n ¼ 91)
ACC/AHA risk based 96 15 Reference Reference Reference
CAC guided (PCE risk <15%) 97 25 1 0.56 10 <0.0001 0.11 <0.0001
CAC guided (no upper risk limit) 94 37 2 0.42 22 <0.0001 0.20 <0.0001
cPB guided (PCE risk <15%) 91 21 4 0.04 6 <0.0001 0.02 0.42
cPB guided (no upper risk limit) 89 31 7 0.01 16 <0.0001 0.09 0.001
CVD (n ¼ 138)
ACC/AHA risk based 96 15 Reference Reference Reference
CAC guided (PCE risk <15%) 94 25 2 0.26 10 <0.0001 0.08 <0.0001
CAC guided (no upper risk limit) 88 37 8 0.005 22 <0.0001 0.14 <0.0001
cPB guided (PCE risk <15%) 91 21 4 0.01 6 <0.0001 0.02 0.30
cPB guided (no upper risk limit) 86 31 10 0.0002 16 <0.0001 0.06 0.04
*Cut-points for disease-guided reclassiﬁcation are CAC ¼ 0 or cPB ¼ 0 for down-classiﬁcation from statin eligible to ineligible and CAC $100 or cPB $300 mm2 for up-
classiﬁcation from optional to clear statin eligible; 2 strategies are shown for each imaging modality, with and without an upper risk limit for down-classiﬁcation.
ACC/AHA ¼ American College of Cardiology/American Heart Association; NRI ¼ net reclassiﬁcation index (Dsensitivity þ Dspeciﬁcity); PCE ¼ Pooled Cohort Equations; other
abbreviations as in Tables 2 and 4.
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888SENSITIVITY ANALYSIS. In study participants who
were not on lipid-lowering drugs at baseline exami-
nation (n ¼ 3,814), 60 CHD and 95 CVD events were
observed during follow-up (Online Table 11). The
relationship between subclinical atherosclerosis and
clinical events (HRs, Online Table 12) and disease-
guided reclassiﬁcation (NRI up to 0.20 for CHD and
0.14 for CVD, Online Table 13) remained similar to the
overall results.
Among individuals already on lipid-lowering drugs
at baseline examination, those with CAC ¼ 0 or
cPB ¼ 0 had low event rates per 1,000 person-years
(0 or 0 for CHD and 3.2 or 3.1 for CVD, respectively),
and those with CAC $100 or cPB $300 mm2 had
relatively high event rates (10.6 or 9.7 for CHD and
13.1 or 11.9 for CVD, respectively).
DISCUSSION
In the contemporary BioImage cohort, 86% had a 10-
year ASCVD risk $7.5% and qualiﬁed for primary
prevention with statins. This ACC/AHA risk-based
approach to statin allocation showed high sensi-
tivity (96%) but low speciﬁcity (15%). Event rates
were low in those without detectable atherosclerosis.
Using a simple disease-guided reclassiﬁcation
approach based on well-deﬁned cut-points for CAC
(and corresponding cPB cut-points) led to a substan-
tial gain in speciﬁcity (less overtreatment) with no or
only minor loss in sensitivity. In this elderly cohort,
CAC performed better than cPB. The binary NRI was
up to 0.20 for CHD events, driven primarily by with-
holding statins in those with CAC ¼ 0. Limiting pri-
mary prevention with statins to individuals with CAC
>0 could spare 1 in 4 elderly patients from taking
medication that will beneﬁt only a few.
STATIN THERAPY FOR ALL ELDERLY PEOPLE? Because
ASCVD risk is strongly age-dependent, Wald and Law
(15) suggested in 2003 that everyone $55 years of age
should be offered treatment with safe risk-reducing
drugs. By introducing a treatment threshold as low
as 7.5% 10-year ASCVD risk, the ACC/AHA guidelines
indirectly supported such a “universal” treatment
principle because everyone with optimal risk factors
will now qualify for statin therapy if they live long
enough (African-American [AA] men age 66 years,
non-AA men age 63 years, AA women age 70 years,
and non-AA women age 71 years) (3,5). However, the
ACC/AHA guidelines remind clinicians that primary
prevention with statins should not only depend on
predicted risk, but also include a discussion with the
individual patient regarding potential treatment
beneﬁts, adverse effects, drug–drug interactions, and
patient preferences (2).PREVIOUS VERSUS NEW ACC/AHA GUIDELINES. The
previous ACC/AHA guidelines for cardiovascular risk
assessment found it reasonable to measure CAC
and carotid intima-media thickness (cIMT) for risk
assessment in asymptomatic adults at intermediate
risk (14). This Class IIa recommendation for imaging-
guided risk assessment was, however, changed to
Class IIb for CAC and Class III for cIMT in the 2013 ACC/
AHA guidelines (2), primarily because the evidence for
clinical utility vanished with the lower threshold for
statin therapy (dwarﬁng the intermediate-risk group
[16]) and the change of predicted outcome from CHD to
ASCVD (CHD and stroke combined). The 2013 ACC/
AHA Class III recommendation for cIMT was based on
evidence provided by a single meta-analysis of the
incremental predictive value of the mean common
cIMT without separate plaque detection and assess-
ment, thus disregarding the known predictive power
of carotid plaque imaging (17).
In the present study, rather than reviving a larger
intermediate group population of uncertain risk, we
accepted the new Class I indication for risk-based
statin therapy ($7.5% 10-year ASCVD risk estimated
by the ACC/AHA risk calculator) as a useful starting
point, and then reclassiﬁed people across the 7.5% risk
threshold guided by the absence or presence of sub-
clinical atherosclerosis. Reclassiﬁcation from statin
eligible to ineligible and vice versa relied solely on
disease-based cut-points (CAC of 0 and 100) that have
documented incremental predictive value beyond
traditional risk factor scoring (18–21). This approach
performed well for both CHD and CVD outcomes,
probably because most CVD events are CHD events.
Individualized statin therapy in the elderly is
important for several reasons. Although universal
treatment of all Americans ages 75 to 94 years might
be cost effective (22), elderly patients are more
vulnerable to statin-related adverse effects because
of comorbidity, polypharmacy, and risk for functional
limitation and possible cognitive impairment. Long-
term effects of using low-dose computed tomogra-
phy for CAC screening are less concerning in the
elderly. Overall, such considerations are obvious
topics for the patient-clinician discussion espoused
by recent guidelines (2).
DOWNWARD RECLASSIFICATION IN THE ABSENCE
OF ATHEROSCLEROSIS. The Class IIb option in the
2013 ACC/AHA guidelines for using CAC for reﬁned
risk assessment when a risk-based treatment decision
is uncertain applies only for up- and not down-
classiﬁcation of risk. In fact, these guidelines pro-
vide little guidance on how to personalize risk
assessment to avoid overtreating healthy individuals
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normal aging.
Although most cardiovascular events occur in old
age, many elderly patients do not have the underlying
disease (atherosclerosis) responsible for the age-
related risk for ASCVD. In the BioImage population
(mean age 69 years), 86% qualiﬁed for risk-based
statin therapy, but imaging revealed that up to one-
third had no CAC, which was associated with a low
cardiovascular event rate, even in patients with dia-
betes. Thus, there was a major gain in speciﬁcity (less
overtreatment) by down-classifying those with $7.5%
10-year ASCVD risk estimated by PCE from statin
eligible to ineligible if CAC was 0, not only in those
with a borderline increased risk (PCE risk from 7.5% to
15%), but also in everyone with a PCE risk$7.5%. Thus,
our study conﬁrmed that CAC ¼ 0 in asymptomatic
people without known ASCVD is associated with a very
low cardiovascular risk, called the power of zero (19).
Our data extended this observation to a contemporary
elderly population with a 10-year ASCVD risk well
above the 7.5% (Class I) risk threshold for statin
therapy.
Few studies have evaluated the potential effect of
atherosclerosis imaging on statin allocation after
formal risk assessment as recommended by the new
ACC/AHA guidelines. In the less contemporary MESA
(Multi-Ethnic Study of Atherosclerosis) cohort of in-
dividuals who were on average 10 years younger than
those in our study, of those eligible for statin therapy
per the 2013 ACC/AHA guidelines, 41% had CAC ¼ 0
and a low ASCVD event rate (5.2 events per 1,000
person-years of follow-up) (23). Among a small
excluded subgroup of MESA participants 75 years of
age, almost all of whom were statin eligible, 18% had
CAC ¼ 0 and a low 10-year event rate. In an even
younger cohort from the Framingham Heart Study, a
CAC score of 0 identiﬁed a large low-risk group (33%)
among the ACC/AHA statin-eligible participants (21).
Our results from a contemporary elderly population
agreed with these recent observations and provided
clinically important performance measures for statin
allocation, such as sensitivity, speciﬁcity, and NRI.
UPWARD RECLASSIFICATION IN THE PRESENCE OF
SIGNIFICANT ATHEROSCLEROSIS. The ACC/AHA
guidelines state that CAC $300 or $75th percentile for
age, sex, and ethnicity may be considered for up-
classiﬁcation of risk in selected individuals (Class IIb
recommendation) (2). Although this approach may be
useful in some younger people (24), there is little room
formeaningful up-classiﬁcation of risk in older people,
asmost already qualify for risk-based statin therapy. In
the BioImage cohort, only 14% had a 10-year ASCVDrisk <7.5%. In this lower-risk subpopulation, we
observed 4 CHD and 6 CVD events during follow-up, 2
of which would have been identiﬁed by the CAC-based
screening approach, none by the cPB-based screening
approach. Thus, the intermediate-risk strategy sup-
ported by the previous ACC/AHA guidelines (14) may
still be relevant as assessed by the NNS, but relatively
few elderly will beneﬁt from such a strategy.
In the younger MESA cohort, the performance of
the guideline-recommended cut-points for up-
classiﬁcation was recently tested using recalibrated
PCEs (25), which is applicable only to MESA and
therefore not generalizable to routine clinical practice
like the present disease-guided proposal. In the MESA
cohort, only a small subgroup (6.8%) was up-
classiﬁed, becoming eligible for primary prevention
with statins.
DISEASE-GUIDED RECLASSIFICATION. The clinical
utility of detecting CAC and carotid plaque differs
(26). If the goal is to predict CHD events, CAC is likely
the optimal imaging test, whereas carotid plaque
assessment may be superior for stroke prediction (27).
However, PCE was devised to predict CHD and stroke
combined (ASCVD), and this study is the ﬁrst to
compare the incremental predictive value of CAC and
carotid plaque imaging beyond formal PCE-based risk
assessment. Judged by the NRI, CAC performed better
than cPB in terms of predicting both CHD events
alone and the combined ASCVD outcome.
A major strength of the present analysis is that we
did not evaluate the clinical performance of imaging
cut-points derived from the BioImage study, but
instead used CAC cut-points of proven value across
multiple populations (18–21). We compared CAC and
cPBwith the same proportion of participants in the top
category deﬁned by imaging. Although the cPB cut-
point of 300 mm2 corresponding to CAC ¼ 100 may
not be the optimal cut-point for the up-classiﬁcation of
risk based on cPB, the main drivers of the positive NRI
in this cohort were CAC ¼ 0 and cPB ¼ 0.
As previously described in greater detail, we used a
novel, highly sensitive ultrasound-based sweep
method to detect atherosclerosis in the carotid ar-
teries (13). It may not necessarily be advantageous in
elderly people, most of whom have at least early
atherosclerotic changes somewhere in the vascula-
ture. Thus, in the BioImage cohort, more people had
cPB >0 (77%) than CAC >0 (68%). However, in a
younger cohort, early detection may be prioritized
together with the use of a method not requiring ra-
diation. The ongoing PESA (Progression of Early
Subclinical Atherosclerosis) study, in which
multiple vascular beds are screened for subclinical
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In elderly people with no
clinical history of atherosclerosis, the absence of
coronary calciﬁcation and carotid plaque is associated
with a low risk of cardiovascular events and might
reasonably lead to a decision to forego statin therapy.
TRANSLATIONAL OUTLOOK: More work is
needed to prospectively evaluate the outcomes of
clinical decision strategies that individualize selection
of preventive therapy based on a combination of
population-based risk estimates and efﬁcient incor-
poration of noninvasive imaging tests.
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the cost of an atherosclerosis imaging test, most
people are ready to pay the cost of a test to avoid
taking a pill each day for the rest of their lives (29).
Another strength of the present study was that it
built on the existing ACC/AHA guidelines, including
the online risk calculator. Furthermore, the tested
disease-guided reclassiﬁcation approach is simple, is
easy to implement clinically, is less dependent on a
well-calibrated risk calculator, uses the strong evi-
dence for low ASCVD risk universally across pop-
ulations if CAC is 0, and focuses on the growing
elderly, resource-consuming, at-risk population.
STUDY LIMITATIONS. PCEs were designed to predict
the natural history of ASCVD in the absence of inter-
vention. A problem BioImage shared with other
contemporary cohorts was the lower-than-expected
event rates, which may be at least partly explained
by the “healthy volunteer effect” andmodern common
use of preventive therapies in people free of ASCVD
(8–10,30). We included coronary revascularization in
the composite endpoints but recognize that knowl-
edge of a high CAC score shared with the patient
and/or physicians may in itself lead to revasculariza-
tion. However, excluding revascularization from the
composite endpoints did not change the study con-
clusions. The durability of our short-term results may
be questioned, but growing evidence indicates that
the “warranty period” for CAC ¼ 0 may be as long as
15 years (20,31), likely indicating lifelong low risk in
elderly people. CAC ¼ 0 is well-deﬁned and repro-
ducible, whereas cBP ¼ 0 is less well-deﬁned and
depends on the protocol used to scan the carotid ar-
teries; our use of a sensitive ultrasound protocol may
explain why cPB ¼ 0 was less common than CAC ¼ 0.CONCLUSIONS
In individuals who qualiﬁed for ACC/AHA risk-based
statin therapy, limiting treatment to those with CAC
>0 or cPB >0 led to a substantial gain in speciﬁcity
(less overtreatment) with no or only a minor loss
in sensitivity. There was not much room for disease-
based expansion of statin eligibility in this elderly
cohort. A simple, individualized, disease-guided ap-
proach to statin allocation could potentially spare a
signiﬁcant proportion of asymptomatic elderly people
from lifelong treatment of questionable beneﬁt.
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